Create a narrative

Protalix BioTherapeutics Community

NYSEAM:PLX Community

4 Narratives written by author
0 Comments on narratives written by author
38 Fair Values set on narratives written by author

Create a narrative

Protalix BioTherapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

PRX-115 Trials And Elfabrio Launch Will Open Future Markets

Key Takeaways Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption. Strengthened balance sheet from debt repayment and cash increase supports growth initiatives and boosts long-term earnings potential.

US$14.50

FV

79.6% undervalued

54.71%

Revenue growth p.a.

0

0

0

1 day ago